Compare Marsh & McLennan Companies, Inc. (MRSH) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Natera Inc. Common Stock — how do they compare? Marsh & McLennan Companies, Inc. trades at $183.86 (market cap $85.13B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Marsh & McLennan Companies, Inc. is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays a 2.22% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Natera Inc. Common Stock for 0 Days on average.
| MRSH | NTRA | |
|---|---|---|
Market Cap | $85.13B | $57.03B |
Volume | 2,472,018 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $203.85 | $425.64 |
52-Week Low | $157.32 | $179.42 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $105.82B | $56.18B |
Dividend Yield | 2.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $177.01, up 0.27% on the day, with a bullish technical signal and strong fundamentals. The company reported revenue of $26.98 billion in 2025, with net income of $4.16 billion and a net margin of 15.41%. Recent earnings have consistently beaten estimates, and the company completed the acquisition of Accel Holdings in October 2026, signaling growth initiatives. Valuation ratios include a P/E of 21.61 and P/S of 3.09, while analyst consensus price target is $202.71.
The outlook for MRSH is positive, supported by earnings beats and strategic acquisitions, but risks include competitive pressures and potential margin compression. Analyst sentiment is mixed with a 'Hold' consensus, suggesting cautious optimism. The stock offers upside to the price target but faces execution risks in integrating acquisitions and maintaining profitability amid economic uncertainties.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
